In a systematic review and meta-analysis, researchers assessed the efficacy of various electrical stimulation therapy treatments in alleviating pain among patients with MS.

Researchers sought to investigate the rates and reasons for dimethyl fumarate discontinuation among patients with MS on a national level and differences between sites in Denmark.

In a systematic review and meta-analysis, researchers assessed randomized controlled trials on the effectiveness of remote forms of exercise and physiotherapy on the depressive symptoms of patients with MS.

These findings are independent of clinical multiple sclerosis relapse.

Researchers sought to compare the rates of COVID-19-related hospitalization and mortality among patients with MS and those without MS.

In a nationwide French study, researchers assessed whether vaccination was associated with the risk for hospitalization due to MS flare-ups.

Researchers sought to assess the association between disability, fatigue, and accelerometer-measured physical activity among patients with RRMS.

In an observational study, researchers investigated the efficacy of rituximab/ocrelizumab suspension preconception vs natalizumab during pregnancy in reactivating multiple sclerosis.

In a double-blind, placebo, randomized clinical trial, researchers assessed the efficacy of teriflunomide in delaying multiple sclerosis progression in patients with radiologically isolated syndrome.

Disease-modifying therapies have minimal transfer into breast milk and is safe and well-tolerated by both the mother and the baby, a study found.

In a systematic review and meta-analysis, researchers assessed whether noninvasive brain stimulation can effectively reduce the most common symptoms in patients with multiple sclerosis.

The Food and Drug Administration has approved Tyruko (natalizumab-sztn), a biosimilar to Tysabri (natalizumab).

Researchers evaluated patient perceptions of the ketogenic diet. The analysis included 3-month follow-up from 52 participants with relapsing multiple sclerosis previously enrolled in a prospective 6-month ketogenic diet trial.

Researchers sought to determine if and when disease-modifying therapies should be discontinued in older adults with multiple sclerosis.

Amino acid metabolism is altered in people with multiple sclerosis and influenced by the clinical type of disease.

Researchers sought to examine the association between patients’ disability, fatigue, and accelerometer-measured physical activity.

The FDA has accepted for review the NDA for glatiramer acetate depot 40 mg for the treatment of relapsing forms of multiple sclerosis.

There is not enough evidence to support the use of spinal cord stimulation over the current medical standard of care to reduce spasticity linked to MS.

Oral disease-modifying therapies (DMTs) predominated new initiations for treatment of multiple sclerosis (MS) in 2020.

In a meta-analysis, researchers evaluated the relationship between Chlamydia pneumoniae infection and the development of multiple sclerosis.

For patients with MS with a first demyelinating event, earlier treatment initiation is associated with a reduction in the risk for long-term disability.

Positive data were announced from a phase 3 trial evaluating an investigational SC formulation of ocrelizumab in patients with MS.

In a cross-sectional study, researchers assessed global data surrounding MS diagnosis from the Multiple Sclerosis International Federation (MSIF) third edition of the Atlas of MS survey.

In a retrospective data analysis, researchers examined the extent to which a twice-daily alertness test is associated with fatigue related to multiple sclerosis.

Researchers assessed the relapse rates among patients with highly active relapsing multiple sclerosis who received treatment with either cladribine or fingolimod.

For people with MS, a pro-inflammatory diet is linked to worsening relapse rate and greater periventricular fluid-attenuated inversion recovery lesion volume.

An evaluation reviewed the connection between OCT findings and the course of multiple sclerosis.

Researchers described the prevalence of cannabis use in adults with chronic pain condition and multiple sclerosis.

For patients with relapsing-remitting multiple sclerosis (MS), rituximab is not noninferior to ocrelizumab.

White individuals have the highest prevalence of multiple sclerosis (MS), according to a study published online.